Roche and Takeda’s Techpool to maximize Bondronat in China
This article was originally published in Scrip
Roche has signed a contract with Takeda subsidiary Techpool Bio that will allow the Chinese pharma company exclusively to market the Swiss firm's oral bisphosphonate drug for bone metastases Bondronat (ibandronic acid) in China. The initial deal runs to 2017, with renewal possible depending on the performance of the product.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.